Literature DB >> 31980982

Gene expression profiling revealed MCM3 to be a better marker than Ki67 in prognosis of invasive ductal breast carcinoma patients.

Yue Zhao1,2, Yimin Wang3, Fudi Zhu1, Jiayu Zhang4, Xiao Ma5, Dongwei Zhang6.   

Abstract

Invasive ductal carcinoma (IDC) is the most common breast cancer. Our study used gene microarray data to select differentially expressed genes between normal and IDC mammary tissues. From these, we selected genes related to the proliferation of tumor cells and compared their prognostic value with known biomarker Ki67 for IDC. Analysis of publicly available Gene Expression Omnibus (GEO) data revealed 24 differentially expressed genes (DEGs) in normal and 31 DEGS in IDC tissues that were used for further analyses. Gene chip analysis software was used to identify DEGs. DEG profiles were confirmed using quantitative PCR (qPCR). DEG functions where shown to be related to cell proliferation. We confirmed MCM3 expression using immunohistochemical staining in 45 IDC patients. The relationship between MCM3 expression and survival was investigated using Kaplan-Meier survival curves and Cox proportional hazard regression models. A total of 1307 differentially expressed genes were identified between IDC and normal tissues, which were enriched in 32 Gene Ontology (GO) terms and 9 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. qPCR demonstrated that both COL1A1 and MCM3 were significantly up-regulated in IDC tissues, of which only MCM3 was related to cell proliferation. Ki67 is closely associated with the tumor grade, ER status, PR status and HER2 status, while MCM3 was shown to relate to tumor size, lymph node, and PR status. There was significant association between survival and MCM3, but not for Ki67. High MCM3 expression demonstrated statistically significant associations with poor prognosis in IDC patients. Findings from the gene microarray data analysis confirmed that MCM3 is associated with the response to cell proliferation. MCM3 represents a better proliferation marker than Ki67 making it a valuable prognostic tool that is independent of ER and HER2 status.

Entities:  

Keywords:  Cell proliferation; Gene microarray data; Invasive ductal carcinoma; Ki67; MCM3

Mesh:

Substances:

Year:  2020        PMID: 31980982     DOI: 10.1007/s10238-019-00604-4

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  26 in total

1.  The application of gene co-expression network reconstruction based on CNVs and gene expression microarray data in breast cancer.

Authors:  Yan Xu; Huizi Duanmu; Zhiqiang Chang; Shanzhen Zhang; Zhenqi Li; Zihui Li; Yufeng Liu; Kening Li; Fujun Qiu; Xia Li
Journal:  Mol Biol Rep       Date:  2011-05-25       Impact factor: 2.316

2.  New single nucleotide polymorphisms (SNPs) in homologous recombination repair genes detected by microarray analysis in Polish breast cancer patients.

Authors:  Hanna Romanowicz; Dominik Strapagiel; Marcin Słomka; Marta Sobalska-Kwapis; Ewa Kępka; Anna Siewierska-Górska; Marek Zadrożny; Jan Bieńkiewicz; Beata Smolarz
Journal:  Clin Exp Med       Date:  2016-11-30       Impact factor: 3.984

Review 3.  Ki67 in breast cancer: prognostic and predictive potential.

Authors:  Rinat Yerushalmi; Ryan Woods; Peter M Ravdin; Malcolm M Hayes; Karen A Gelmon
Journal:  Lancet Oncol       Date:  2010-02       Impact factor: 41.316

4.  Expression of tetraspanins NET-6 and CD151 in breast cancer as a potential tumor biomarker.

Authors:  Liejun Jiang; Xiliu Zhang; Joseph Geradts; Qiang Wei; Steven Hochwald; Hui Xu; Huayi Huang
Journal:  Clin Exp Med       Date:  2019-04-20       Impact factor: 3.984

Review 5.  First among equals: the cancer cell hierarchy.

Authors:  Christine V Ichim; Richard A Wells
Journal:  Leuk Lymphoma       Date:  2006-10

Review 6.  MCM proteins as diagnostic and prognostic tumor markers in the clinical setting.

Authors:  Constantinos Giaginis; Stephanie Vgenopoulou; Philippe Vielh; Stamatios Theocharis
Journal:  Histol Histopathol       Date:  2010-03       Impact factor: 2.303

7.  Minichromosome maintenance protein 3 is a candidate proliferation marker in papillary thyroid carcinoma.

Authors:  Youn Soo Lee; Seon-Ah Ha; Hae Joo Kim; Seung Min Shin; Hyun Kee Kim; Sanghee Kim; Chang Suk Kang; Kyo Young Lee; Oak Kee Hong; Seung-Hwan Lee; Hyuk-Sang Kwon; Bong-Yun Cha; Jin Woo Kim
Journal:  Exp Mol Pathol       Date:  2009-10-08       Impact factor: 3.362

8.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.

Authors:  Mitch Dowsett; Torsten O Nielsen; Roger A'Hern; John Bartlett; R Charles Coombes; Jack Cuzick; Matthew Ellis; N Lynn Henry; Judith C Hugh; Tracy Lively; Lisa McShane; Soon Paik; Frederique Penault-Llorca; Ljudmila Prudkin; Meredith Regan; Janine Salter; Christos Sotiriou; Ian E Smith; Giuseppe Viale; Jo Anne Zujewski; Daniel F Hayes
Journal:  J Natl Cancer Inst       Date:  2011-09-29       Impact factor: 13.506

9.  An international Ki67 reproducibility study.

Authors:  Mei-Yin C Polley; Samuel C Y Leung; Lisa M McShane; Dongxia Gao; Judith C Hugh; Mauro G Mastropasqua; Giuseppe Viale; Lila A Zabaglo; Frédérique Penault-Llorca; John M S Bartlett; Allen M Gown; W Fraser Symmans; Tammy Piper; Erika Mehl; Rebecca A Enos; Daniel F Hayes; Mitch Dowsett; Torsten O Nielsen
Journal:  J Natl Cancer Inst       Date:  2013-11-07       Impact factor: 13.506

10.  Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups.

Authors:  Mustapha Abubakar; Nick Orr; Frances Daley; Penny Coulson; H Raza Ali; Fiona Blows; Javier Benitez; Roger Milne; Herman Brenner; Christa Stegmaier; Arto Mannermaa; Jenny Chang-Claude; Anja Rudolph; Peter Sinn; Fergus J Couch; Peter Devilee; Rob A E M Tollenaar; Caroline Seynaeve; Jonine Figueroa; Mark E Sherman; Jolanta Lissowska; Stephen Hewitt; Diana Eccles; Maartje J Hooning; Antoinette Hollestelle; John W M Martens; Carolien H M van Deurzen; Manjeet K Bolla; Qin Wang; Michael Jones; Minouk Schoemaker; Jelle Wesseling; Flora E van Leeuwen; Laura Van 't Veer; Douglas Easton; Anthony J Swerdlow; Mitch Dowsett; Paul D Pharoah; Marjanka K Schmidt; Montserrat Garcia-Closas
Journal:  Breast Cancer Res       Date:  2016-10-18       Impact factor: 6.466

View more
  8 in total

1.  MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.

Authors:  Eun Young Kang; Joshua Millstein; Gordana Popovic; Nicola S Meagher; Adelyn Bolithon; Aline Talhouk; Derek S Chiu; Michael S Anglesio; Betty Leung; Katrina Tang; Neil Lambie; Marina Pavanello; Annalyn Da-Anoy; Diether Lambrechts; Liselore Loverix; Siel Olbrecht; Christiani Bisinotto; Jesus Garcia-Donas; Sergio Ruiz-Llorente; Monica Yagüe-Fernandez; Robert P Edwards; Esther Elishaev; Alexander Olawaiye; Sarah Taylor; Beyhan Ataseven; Andreas du Bois; Philipp Harter; Jenny Lester; Claus K Høgdall; Sebastian M Armasu; Yajue Huang; Robert A Vierkant; Chen Wang; Stacey J Winham; Sabine Heublein; Felix K F Kommoss; Daniel W Cramer; Naoko Sasamoto; Lilian van-Wagensveld; Maria Lycke; Constantina Mateoiu; Janine Joseph; Malcolm C Pike; Kunle Odunsi; Chiu-Chen Tseng; Celeste L Pearce; Sanela Bilic; Thomas P Conrads; Arndt Hartmann; Alexander Hein; Michael E Jones; Yee Leung; Matthias W Beckmann; Matthias Ruebner; Minouk J Schoemaker; Kathryn L Terry; Mona A El-Bahrawy; Penny Coulson; John L Etter; Katherine LaVigne-Mager; Juergen Andress; Marcel Grube; Anna Fischer; Nina Neudeck; Greg Robertson; Rhonda Farrell; Ellen Barlow; Carmel Quinn; Anusha Hettiaratchi; Yovanni Casablanca; Ramona Erber; Colin J R Stewart; Adeline Tan; Yu Yu; Jessica Boros; Alison H Brand; Paul R Harnett; Catherine J Kennedy; Nikilyn Nevins; Terry Morgan; Peter A Fasching; Ignace Vergote; Anthony J Swerdlow; Francisco J Candido Dos Reis; G Larry Maxwell; Susan L Neuhausen; Arantzazu Barquin-Garcia; Francesmary Modugno; Kirsten B Moysich; Philip J Crowe; Akira Hirasawa; Florian Heitz; Beth Y Karlan; Ellen L Goode; Peter Sinn; Hugo M Horlings; Estrid Høgdall; Karin Sundfeldt; Stefan Kommoss; Annette Staebler; Anna H Wu; Paul A Cohen; Anna DeFazio; Cheng-Han Lee; Helen Steed; Nhu D Le; Simon A Gayther; Kate Lawrenson; Paul D P Pharoah; Gottfried Konecny; Linda S Cook; Susan J Ramus; Linda E Kelemen; Martin Köbel
Journal:  Virchows Arch       Date:  2021-11-15       Impact factor: 4.535

2.  MicroRNA-186-3p attenuates tumorigenesis of cervical cancer by targeting MCM2.

Authors:  Xiurong Lu; Xiao Song; Xiaohui Hao; Xiaoyu Liu; Xianyu Zhang; Na Yuan; Huan Ma; Zhilin Zhang
Journal:  Oncol Lett       Date:  2021-05-19       Impact factor: 2.967

3.  Identification of hub genes and biological pathways in hepatocellular carcinoma by integrated bioinformatics analysis.

Authors:  Qian Zhao; Yan Zhang; Shichun Shao; Yeqing Sun; Zhengkui Lin
Journal:  PeerJ       Date:  2021-01-19       Impact factor: 2.984

4.  Multiomics profiling of the expression and prognosis of MCMs in endometrial carcinoma.

Authors:  Hua Lan; Jing Yuan; Xingyu Chen; Chu Liu; Xiaohui Guo; Xinyu Wang; Jiarui Song; Ke Cao; Songshu Xiao
Journal:  Biosci Rep       Date:  2021-12-22       Impact factor: 3.840

5.  Systematic analysis of MCM3 in pediatric medulloblastoma via multi-omics analysis.

Authors:  Liangliang Cao; Yang Zhao; Zhuangzhuag Liang; Jian Yang; Jiajia Wang; Shuangwei Tian; Qinhua Wang; Baocheng Wang; Heng Zhao; Feng Jiang; Jie Ma
Journal:  Front Mol Biosci       Date:  2022-09-05

6.  A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.

Authors:  Masanori Oshi; Fernando A Angarita; Yoshihisa Tokumaru; Li Yan; Ryusei Matsuyama; Itaru Endo; Kazuaki Takabe
Journal:  Cancers (Basel)       Date:  2021-05-16       Impact factor: 6.639

7.  Identification of the DNA Replication Regulator MCM Complex Expression and Prognostic Significance in Hepatic Carcinoma.

Authors:  Ting Cao; Shi-Jie Yi; Li-Xin Wang; Juan-Xia Zhao; Jiao Xiao; Ni Xie; Zhi Zeng; Qi Han; Hai-Ou Tang; Yu-Kun Li; Juan Zou; Qing Wu
Journal:  Biomed Res Int       Date:  2020-09-09       Impact factor: 3.411

8.  ZMIZ2 promotes the development of triple-receptor negative breast cancer.

Authors:  Xiaopan Zou; Yan Liu; Jun Di; Wei Wei; Nobumoto Watanabe; Jiang Li; Xiaomeng Li
Journal:  Cancer Cell Int       Date:  2022-01-31       Impact factor: 5.722

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.